NCT07138001View on ClinicalTrials.gov

Phase 2 Clinical Trial of KH617

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2030

Conditions
Recurrent Glioblastoma
Interventions
COMBINATION_PRODUCT

KH617+TMZ

use KH617 and TMZ(5/28) as Combination Product.

DRUG

KH617

Single Clinical trial investigational drug

DRUG

TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

"Comparator product, Two treatment options for physicians and subjects to choose from:~1. use TMZ(7/7)~2. Use Platinum (cisplatin or carboplatin)+VP-16"

All Listed Sponsors
lead

Sichuan Honghe Biotechnology Co., Ltd.

INDUSTRY